A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice

Sponsor
Novo Nordisk A/S
Study ID
NCT05443334
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.

Study Details

The purpose of the study is to collect information on participant's blood sugar levels, body weight, how satisfied participant is with the treatment, and how participant takes his/her diabetes medicines. Participant will get Rybelsus® as prescribed by study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.

Key Dates

Start date
Jul 28, 2022
Status verified
Sep 2025
Primary completion
Jul 4, 2024
Completion
Jul 4, 2024

Study Design

Enrollment
465 participants (actual)

Arms

  • Arm: Participants with type 2 diabetes
    Participants with type 2 diabetes and naive to injectable glucose-lowering treatment.

Primary Outcome Measure

Change in HbA1c [ Time Frame: From baseline (week 0) to End of Study visit (V3) (week 34-44) ]

Related Studies